Instructions for Ulcavis (Bismuth tripotassium dicitrate) tablets
English product name
Ulcavis
Release Form
Shell-coated tablets
Description Ulcavis
The tablets, covered with a shell of white or almost white color, are round, double-convex, with a chamfer; the view on the fracture is a rough mass of white color with a shell of white or almost white color.
1 tab.
bismuth tripotassium dicitrate 303.03 mg,
which corresponds to the content of bismuth oxide 120 mg
Auxiliary substances: cornstarch - 72.17 mg, Povidone K30 - 18 mg, potassium polycrylene - 23.8 mg, macrogol 6000 - 6 mg, magnesium stearate - 2 mg.
Film sheath composition: opadray II transparent - 8.5 mg (polyvinyl alcohol - 4.505 mg, macrogol 4000 - 2.295 mg, talc - 1.7 mg), titanium dioxide (E171) - 1.5 mg.
ATC codes
A02BX05 Bismuth subcitrate
Clinical-pharmacological groups / Group affiliation Ulcavis
Preparation having a protective effect on the mucosa of the stomach and duodenum. Antiulcer preparation
Active substance
bismuth tripotassium dicitrate
Pharmaco-therapeutic group Ulcavis
Antiseptic intestinal and astringent agent
Pharmacological effect Ulcavis
Antiulcer agent with bactericidal activity with respect to Helicobacter pylori. It also has an anti-inflammatory and astringent effect. In the acidic environment of the stomach, it forms insoluble bismuth oxychloride and citrate
Testimony Ulcavis
- Gastritis and duodenal ulcer in the exacerbation phase (including those associated with Helicobacter pylori);
- chronic gastritis and gastroduodenitis in the exacerbation phase (including those associated with Helicobacter pylori);
- irritable bowel syndrome,
- which proceeds predominantly with diarrhoea symptoms;
- functional dyspepsia,
- not associated with organic gastrointestinal diseases.
Method of use, course and dosage Ulcavis
Adults and children over four years old - inside two - four times/day for thirty minutes before meals. The dose depends on the patient's age.
The treatment is four to eight weeks. Do not take bismuth-containing medication for the next eight weeks.
The use of dicitrate tripotassium bismuth in combination with antibacterial preparations having anti-helicobacter activity is expedient for the eradication of Helicobacter pylori.
- Nosology (ICD codes)
- K25
- Stomach ulcer
- K26
- Duodenum ulcer
- K27
- Peptic ulcer
- K29
- Gastritis and duodenitis
- K30
- Functional dyspepsia (digestive disorder)
- K58
- Irritable bowel syndrome
